Apr 5 2013
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received a Notice of Allowance from the U.S. Patent Trade Office (USPTO) on a patent application for the VIBEX™ QuickShot (QS) device, the latest advancement in its proprietary line of VIBEX™ auto-injector systems.
“The size and scope of our intellectual property portfolio continues to grow as we develop device technologies that will enhance the product performance of established drugs as well as new drugs in development.”
Paul K. Wotton, Ph.D., President and Chief Executive Officer, stated, "The size and scope of our intellectual property portfolio continues to grow as we develop device technologies that will enhance the product performance of established drugs as well as new drugs in development." Dr. Wotton continued, "We believe that many injectable drugs currently under development will be administered by self-injection once they reach the market. Our advancing technology will therefore be important for the growing number of chronic care products that can only be given by injection."
The VIBEX™ QS device offers a dose capacity up to 1 mL and the design can be scaled for larger volumes. The device design emphasizes enhanced performance on the attributes most critical to patient success - speed, comfort and discretion. The new design also accommodates fast injection of highly-viscous drug products that stall less-powerful conventional auto-injectors. Many self-injectable biological agents currently marketed and in clinical development are formulated to be administered in a 1 mL dose volume and tend to be of higher viscosity than non-biologic injectable products.
SOURCE Antares Pharma, Inc.
Expanding access to GLP-1 weight-loss drugs could save thousands of lives